Kura Oncology (KURA) Projected to Post Earnings on Thursday

Kura Oncology (NASDAQ:KURA) is projected to release its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect Kura Oncology to post earnings of ($0.56) per share and revenue of $39.08 million for the quarter.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kura Oncology Trading Up 1.2 %

NASDAQ:KURA opened at $6.51 on Tuesday. The firm’s fifty day moving average is $6.85 and its 200-day moving average is $9.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48. The firm has a market cap of $525.86 million, a P/E ratio of -2.76 and a beta of 0.83.

Analysts Set New Price Targets

KURA has been the topic of a number of analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Monday. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday, April 4th. UBS Group decreased their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.